Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme

Trends in Endocrinology and Metabolism

Volumn 28, Issue 5, 2017, Pages 340-353

  Pissios, Pavlos ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE METHYLTRANSFERASE; VITAMIN;

ADIPOSE TISSUE; CAENORHABDITIS ELEGANS; CANCER CELL; EMBRYONIC STEM CELL; ENDOTHELIUM; ENZYME METABOLISM; GENETIC VARIATION; HUMAN; INFLAMMATION; INJURY; LIVER; MEDICAL HISTORY; NONHUMAN; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; ANIMAL; ENZYMOLOGY; GENETICS; METABOLISM; THEORETICAL MODEL;

ADIPOSE TISSUE; ANIMALS; HUMANS; LIVER; MODELS, THEORETICAL; NIACINAMIDE; NICOTINAMIDE N-METHYLTRANSFERASE;

EID: 85014791664     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2017.02.004     Document Type: Review

References (90)

1. 1 Aksoy, S., et al. Human liver nicotinamide N-methyltransferase cDNA cloning, expression, and biochemical characterization. J. Biol. Chem. 269 (1994), 14835–14840.
2. 2 Felsted, R.L., Chaykin, S., N1-methylnicotinamide oxidation in a number of mammals. J. Biol. Chem. 242 (1967), 1274–1279.
3. 3 Real, A.M., et al. Nicotinamide N-oxidation by CYP2E1 in human liver microsomes. Drug Metab. Dispos. 41 (2013), 550–553.
4. 4 Chaykin, S., et al. The fate of nicotinamide in the mouse. Urinary metabolites. J. Biol. Chem. 240 (1965), 932–938.
5. 5 Shibata, K., et al. Niacin catabolism in rodents. J. Nutr. Sci. Vitaminol. (Tokyo) 36 (1990), 87–98.
6. 6 Najjar, V.A., Holt, L.E., The excretion of specific fluorescent substances in the urine in pellagra. Science 93 (1941), 20–21.
7. 7 Sarett, H.P., et al. Studies in nicotinic acid metabolism I. The fate of nicotinic acid in man. J. Nutr. 23 (1942), 23–34.
8. 8 Huff, J.W., Perlzweig, W.A., N1-methylnicotinamide, a metabolite of nicotinic acid in the urine. J. Biol. Chem. 150 (1943), 395–400.
9. 9 Cantoni, G.L., Methylation of nicotinamide with a soluble enzyme system from rat liver. J. Biol. Chem. 189 (1951), 203–216.
10. 10 Cantoni, G.L., The nature of the active methyl donor formed enzymatically from L-methionine and adenosinetriphosphate. J. Am. Chem. Soc. 74 (1952), 2942–2943.
11. 11 Alston, T.A., Abeles, R.H., Substrate specificity of nicotinamide methyltransferase isolated from porcine liver. Arch. Biochem. Biophys. 260 (1988), 601–608.
12. 12 Yan, L., et al. Mouse liver nicotinamide N-methyltransferase: cDNA cloning, expression, and nucleotide sequence polymorphisms. Biochem. Pharmacol. 54 (1997), 1139–1149.
13. 13 Schmeisser, K., et al. Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat. Chem. Biol. 9 (2013), 693–700.
14. 14 Kang-Lee, Y.A., et al. Metabolic effects of nicotinamide administration in rats. J. Nutr. 113 (1983), 215–221.
15. 15 Handler, P., Dann, W.J., The inhibition of rat growth by nicotinamide. J. Biol. Chem. 146 (1942), 357–368.
16. 16 RIKANS, L.L., et al. Fatty livers produced in albino rats by excess niacin in high fat diets. II. Effect of choline supplements. J. Nutr. 85 (1965), 107–112.
17. 17 Henning, S.M., et al. Hepatic content of S-adenosylmethionine, S-adenosylhomocysteine and glutathione in rats receiving treatments modulating methyl donor availability. J. Nutr. 119 (1989), 1478–1482.
18. 18 Kannt, A., et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia 58 (2015), 799–808.
19. 1-methylnicotinamide is associated with obesity and diabetes in Chinese. J. Clin. Endocrinol. Metab. 100 (2015), 3112–3117.
20. 20 Hong, S., et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat. Med. 21 (2015), 887–894.
21. 21 Xu, J., et al. Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1β in human papillary thyroid cancer cells. Mol. Endocrinol. 19 (2005), 527–539.
22. 22 Tomida, M., et al. Stat3 up-regulates expression of nicotinamide N-methyltransferase in human cancer cells. J. Cancer Res. Clin. Oncol. 134 (2008), 551–559.
23. 23 Ghazalpour, A., et al. Hybrid Mouse Diversity Panel: a panel of inbred mouse strains suitable for analysis of complex genetic traits. Mamm. Genome 23 (2012), 680–692.
24. 24 Torgerson, D.G., et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat. Genet. 43 (2011), 887–892.
25. 25 Seshadri, S., et al. Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham study. BMC Med. Genet., 8, 2007, S15.
26. 26 Bromberg, A., et al. Nicotinamide-N-methyltransferase (NNMT) in schizophrenia: genetic association and decreased frontal cortex mRNA levels. Int. J. Neuropsychopharmacol. 15 (2012), 727–737.
27. 27 Wang, G., et al. Female specific association between NNMT gene and schizophrenia in a Han Chinese population. Int. J. Med. Sci. 11 (2014), 1234–1239.
28. 28 Sazci, G., et al. Association of nicotinamide-N-methyltransferase gene rs694539 variant with epilepsy. Mol. Neurobiol. 53 (2015), 4197–4200.
29. 29 Sazci, A., et al. Association of nicotinamide-N-methyltransferase gene rs694539 variant with patients with nonalcoholic steatohepatitis. Genet. Test. Mol. Biomarkers 17 (2013), 849–853.
30. 30 Souto, J.C., et al. A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project. Am. J. Hum. Genet. 76 (2005), 925–933.
31. + precursor vitamins in human nutrition. Annu. Rev. Nutr. 28 (2008), 115–130.
32. + metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22 (2015), 31–53.
33. + metabolism: bioenergetics, signaling and manipulation for therapy. Biochim. Biophys. Acta 1864 (2016), 1787–1800.
34. 34 Bitterman, K.J., et al. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem. 277 (2002), 45099–45107.
35. 35 Clark, J.B., et al. Inhibition of nuclear NAD nucleosidase and poly ADP-ribose polymerase activity from rat liver by nicotinamide and 5′-methyl nicotinamide. Biochim. Biophys. Acta 238 (1971), 82–85.
36. 36 Revollo, J.R., et al. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J. Biol. Chem. 279 (2004), 50754–50763.
37. 37 Burgos, E.S., Schramm, V.L., Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry 47 (2008), 11086–11096.
38. 38 Kraus, D., et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 508 (2014), 258–262.
39. 39 Chang, H.-C., Guarente, L., SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab. 25 (2014), 138–145.
40. 40 Haigis, M.C., Sinclair, D.A., Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5 (2010), 253–295.
41. 41 He, W., et al. Mitochondrial sirtuins: regulators of protein acylation and metabolism. Trends Endocrinol. Metab. 23 (2012), 467–476.
42. 42 Houtkooper, R.H., et al. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13 (2012), 225–238.
43. 43 Rodgers, J.T., et al. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434 (2005), 113–118.
44. 44 Nemoto, S., et al. Nutrient availability regulates SIRT1 through a Forkhead-dependent pathway. Science 306 (2004), 2105–2108.
45. 45 Nemoto, S., et al. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1α. J. Biol. Chem. 280 (2005), 16456–16460.
46. 46 Liu, Y., et al. A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature 456 (2008), 269–273.
47. 47 Li, X., et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28 (2007), 91–106.
48. 48 Ponugoti, B., et al. SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J. Biol. Chem. 285 (2010), 33959–33970.
49. 49 Walker, A.K., et al. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev. 24 (2010), 1403–1417.
50. 50 Parsons, R.B., et al. The expression of nicotinamide N-methyltransferase increases ATP synthesis and protects SH-SY5Y neuroblastoma cells against the toxicity of complex I inhibitors. Biochem. J. 436 (2011), 145–155.
51. 51 Tanaka, Y., et al. 1-Methylnicotinamide ameliorates lipotoxicity-induced oxidative stress and cell death in kidney proximal tubular cells. Free Radic. Biol. Med. 89 (2015), 831–841.
52. 52 Peng, L., et al. Ubiquitinated sirtuin 1 (SIRT1) function is modulated during DNA damage-induced cell death and survival. J. Biol. Chem. 290 (2015), 8904–8912.
53. 53 Chlopicki, S., et al. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br. J. Pharmacol. 152 (2007), 230–239.
54. 54 Domagala, T.B., et al. Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels. Hypertension 59 (2012), 825–832.
55. 55 Kim, H.C., et al. Expression and functional significance of nicotinamide N-methyl transferase in skeletal muscles of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 181 (2010), 797–805.
56. 56 Savarimuthu Francis, S.M., et al. Genes and gene ontologies common to airflow obstruction and emphysema in the lungs of patients with COPD. PLoS One, 6, 2011, e17442.
57. + repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352 (2016), 1436–1443.
58. 58 Sternak, M., et al. Nicotinamide N-methyltransferase (NNMT) and 1-methylnicotinamide (MNA) in experimental hepatitis induced by concanavalin A in the mouse. Pharmacol. Rep. 62 (2010), 483–493.
59. 59 Fedorowicz, A., et al. Activation of the nicotinamide N-methyltransferase (NNMT)–1-methylnicotinamide (MNA) pathway in pulmonary hypertension. Respir. Res., 17, 2016, 108.
60. 60 Jakubowski, A., et al. 1-Methylnicotinamide protects against liver injury induced by concanavalin A via a prostacyclin-dependent mechanism: a possible involvement of IL-4 and TNF-α. Int. Immunopharmacol. 31 (2016), 98–104.
61. 61 Markert, J.M., et al. Differential gene expression profiling in human brain tumors. Physiol. Genomics 5 (2001), 21–33.
62. 62 Xu, J., et al. Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 88 (2003), 4990–4996.
63. 63 Yao, M., et al. Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J. Pathol. 205 (2005), 377–387.
64. 64 Wu, Y., et al. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 27 (2008), 6679–6689.
65. 65 Jang, J.S., et al. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol. Res. 14 (2004), 491–499.
66. 66 Lim, B.-H., et al. Overexpression of nicotinamide N-methyltransferase in gastric cancer tissues and its potential post-translational modification. Exp. Mol. Med. 38 (2006), 455–465.
67. 67 Roessler, M., et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 11 (2005), 6550–6557.
68. 68 Sartini, D., et al. Nicotinamide N-methyltransferase upregulation inversely correlates with lymph node metastasis in oral squamous cell carcinoma. Mol. Med. 13 (2007), 415–421.
69. 69 Kim, J., et al. Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J. Exp. Clin. Cancer Res., 28, 2009, 20.
70. 70 Yu, T., et al. Effects of nicotinamide N-methyltransferase on PANC-1 cells proliferation, metastatic potential and survival under metabolic stress. Cell. Physiol. Biochem. 35 (2015), 710–721.
71. 71 Tang, S.-W., et al. Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis 32 (2011), 138–145.
72. 72 Pozzi, V., et al. RNA-mediated gene silencing of nicotinamide N-methyltransferase is associated with decreased tumorigenicity in human oral carcinoma cells. PLoS One, 8, 2013, e71272.
73. 73 Ulanovskaya, O.A., et al. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nat. Chem. Biol. 9 (2013), 300–306.
74. 74 Palanichamy, K., et al. NNMT silencing activates tumor suppressor PP2A, inactivates oncogenic STKs and inhibits tumor forming ability. Clin. Cancer Res., 2016, 10.1158/1078-0432.ccr-16-1323 Published online November 3, 2016.
75. 75 Sperber, H., et al. The metabolome regulates the epigenetic landscape during naive-to-primed human embryonic stem cell transition. Nat. Cell Biol. 17 (2015), 1523–1535.
76. 76 Riederer, M., et al. Adipose tissue as a source of nicotinamide N-methyltransferase and homocysteine. Atherosclerosis 204 (2009), 412–417.
77. 77 Mato, J.M., et al. Methionine metabolism and liver disease. Annu. Rev. Nutr. 28 (2008), 273–293.
78. 78 Mudd, S.H., et al. Methyl balance and transmethylation fluxes in humans. Am. J. Clin. Nutr. 85 (2007), 19–25.
79. 79 Martínez-Chantar, M.L., Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47 (2008), 1191–1199.
80. 80 Varela-Rey, M., et al. Fatty liver and fibrosis in glycine N-methyltransferase knockout mice is prevented by nicotinamide. Hepatology 52 (2010), 105–114.
81. + precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15 (2012), 838–847.
82. 82 Trammell, S.A.J., et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci. Rep., 6, 2016, 26933.
83. 83 Trammell, S.A.J., et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat. Commun., 7, 2016, 12948.
84. 84 Okamoto, H., et al. Diurnal variations in human urinary excretion of nicotinamide catabolites: effects of stress on the metabolism of nicotinamide. Am. J. Clin. Nutr. 77 (2003), 406–410.
85. +–SIRT1 control of H3K4 trimethylation through circadian deacetylation of MLL1. Nat. Struct. Mol. Biol. 22 (2015), 312–318.
86. 86 Trammell, S.A.J., Brenner, C., NNMT: a bad actor in fat makes good in liver. Cell Metab. 22 (2015), 200–201.
87. + precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 20 (2014), 1059–1068.
88. + intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14 (2011), 528–536.
89. + replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24 (2016), 566–581.
90. 90 Bi, H.-C., et al. N-methylnicotinamide and nicotinamide N-methyltransferase are associated with microRNA-1291-altered pancreatic carcinoma cell metabolome and suppressed tumorigenesis. Carcinogenesis 35 (2014), 2264–2272.